Royalty Pharma Plc Revenue per Employee (RPRX), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Royalty Pharma Plc  (NASDAQ: RPRX)
 

Royalty Pharma Plc's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 10.97% in the first quarter 2026, year on year to cumulative value of $2,441 million, Royalty Pharma Plc's revenue per employee grew on a trailing twelve months basis to $ 24,405,220. The productivity of Royalty Pharma Plc's employees was 0.0%, above the company average.
Within the Healthcare sector employees in only one company have achieved higher revenue/employee than at Royalty Pharma Plc. While Royalty Pharma Plc's total ranking has deteriorated compared to the previous quarter from 5 to 30. Royalty Pharma Plc has 100 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RPRX Revenue per Employee (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Revenue Change 10.97 % 4.78 % 7.9 % 7.71 % 0.05 %
Sales per Employee (TTM) $ 24,405,220 23,781,930 23,498,440 23,052,430 22,638,450
RPRX's Total Ranking # 30 # 5 # 15 # 21 #
Seq. Revenue Change 1.38 % 2.08 % 5.29 % 1.83 % -4.28 %

RPRX Company Profile >> Back to RPRX Efficiency Comparisons >> Compare RPRX Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 2
Healthcare Sector # 2
Overall Market # 30

Revenue per Employee Statistics
High Average Low
$ 27,864,810 $ 14,186,759 $ 60
(Sep 30 2021)   (Sep 30 2015)



Financial Statements
Royalty Pharma Plc's Revenue MRQ $ 631 Millions Visit RPRX's Income Statement
Royalty Pharma Plc's Revenues TTM $ 2,441 Millions Visit RPRX's aggregate revenue growth
What are RPRX's Sales? Visit RPRX's Sales by Segment




Other Ratios
Royalty Pharma Plc's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
RPRX's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for RPRX's Competitors
Revenue per Employee for RPRX's Suppliers
Revenue per Employee for RPRX's Customers

You may also want to know
RPRX's Sales Growth Rates RPRX's Pe Price to earnings ratio RPRX's Receivables Turnover Ratio RPRX's Stock Quote
RPRX's Net Income Growth Rates RPRX's Ps Price to Sales ratio RPRX's Sales per Employee RPRX's Asset Turnover Ratio
RPRX's Net Margin RPRX's Pb Price to Book ratio RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
Date modified: 2026-08-30T15:00:17+00:00




Companies with similar Revenue per Employee for 12 months ending Mar 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Mar 31 2026Number of Employees Mar 31 2026
Vertex Pharmaceuticals Inc  30,167,901.23 $ 12,218.000  Million 405 
Royalty Pharma Plc  24,405,220.00 $ 2,440.522  Million 100 
Pmgc Holdings Inc   16,357,335.88 $ 556.149  Million 34 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.